Cover Image
市場調查報告書

Kareus Therapeutics, SA 產品平台分析

Kareus Therapeutics, SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 319982
出版日期 內容資訊 英文 22 Pages
訂單完成後即時交付
價格
Back to Top
Kareus Therapeutics, SA 產品平台分析 Kareus Therapeutics, SA - Product Pipeline Review - 2015
出版日期: 2015年12月16日 內容資訊: 英文 22 Pages
簡介

Kareus Therapeutics, SA 是總公司在瑞士的生物科技企業,進行老齡化性疾病和慢性疾病為對象的低分子醫藥品的藥物研發及開發。開發中產品有胰島素敏化劑,及老年癡呆症、心臟疾病、代謝系疾病、發炎疾病的治療藥等,在與其他製藥企業的合作下進行開發。

本報告提供Kareus Therapeutics, SA 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Kareus Therapeutics, SA 基本資料

  • Kareus Therapeutics, SA 概要
  • 主要資訊
  • 企業資料

Kareus Therapeutics, SA :R&D概要

  • 主要的治療範圍

Kareus Therapeutics, SA :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Kareus Therapeutics, SA :開發中產品概況

  • 在臨床階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Kareus Therapeutics, SA :藥物簡介

  • KU-046
  • KU-5039
  • Small Molecule for Cancer
  • Small Molecule for Neuropathic Pain and Inflammatory Pain

Kareus Therapeutics, SA :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Kareus Therapeutics, SA :最近的開發平台資訊

Kareus Therapeutics, SA :開發中止的計劃

Kareus Therapeutics, SA :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07877CDB

Summary

Global Markets Direct's, 'Kareus Therapeutics, SA - Product Pipeline Review - 2015', provides an overview of the Kareus Therapeutics, SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Kareus Therapeutics, SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Kareus Therapeutics, SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Kareus Therapeutics, SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Kareus Therapeutics, SA's pipeline products

Reasons to buy

  • Evaluate Kareus Therapeutics, SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Kareus Therapeutics, SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Kareus Therapeutics, SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Kareus Therapeutics, SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Kareus Therapeutics, SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Kareus Therapeutics, SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Kareus Therapeutics, SA Snapshot
    • Kareus Therapeutics, SA Overview
    • Key Information
    • Key Facts
  • Kareus Therapeutics, SA - Research and Development Overview
    • Key Therapeutic Areas
  • Kareus Therapeutics, SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Kareus Therapeutics, SA - Pipeline Products Glance
    • Kareus Therapeutics, SA - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Kareus Therapeutics, SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Kareus Therapeutics, SA - Drug Profiles
    • KU-046
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KU-5039
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Neuropathic Pain and Inflammatory Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Kareus Therapeutics, SA - Pipeline Analysis
    • Kareus Therapeutics, SA - Pipeline Products by Target
    • Kareus Therapeutics, SA - Pipeline Products by Route of Administration
    • Kareus Therapeutics, SA - Pipeline Products by Molecule Type
    • Kareus Therapeutics, SA - Pipeline Products by Mechanism of Action
  • Kareus Therapeutics, SA - Recent Pipeline Updates
  • Kareus Therapeutics, SA - Dormant Projects
  • Kareus Therapeutics, SA - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Kareus Therapeutics, SA, Key Information
  • Kareus Therapeutics, SA, Key Facts
  • Kareus Therapeutics, SA - Pipeline by Indication, 2015
  • Kareus Therapeutics, SA - Pipeline by Stage of Development, 2015
  • Kareus Therapeutics, SA - Monotherapy Products in Pipeline, 2015
  • Kareus Therapeutics, SA - Phase I, 2015
  • Kareus Therapeutics, SA - Preclinical, 2015
  • Kareus Therapeutics, SA - Pipeline by Target, 2015
  • Kareus Therapeutics, SA - Pipeline by Route of Administration, 2015
  • Kareus Therapeutics, SA - Pipeline by Molecule Type, 2015
  • Kareus Therapeutics, SA - Pipeline Products by Mechanism of Action, 2015
  • Kareus Therapeutics, SA - Recent Pipeline Updates, 2015
  • Kareus Therapeutics, SA - Dormant Developmental Projects,2015

List of Figures

  • Kareus Therapeutics, SA - Pipeline by Top 10 Indication, 2015
  • Kareus Therapeutics, SA - Pipeline by Stage of Development, 2015
  • Kareus Therapeutics, SA - Monotherapy Products in Pipeline, 2015
  • Kareus Therapeutics, SA - Pipeline by Top 10 Target, 2015
  • Kareus Therapeutics, SA - Pipeline by Top 10 Route of Administration, 2015
  • Kareus Therapeutics, SA - Pipeline by Top 10 Molecule Type, 2015
  • Kareus Therapeutics, SA - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top